Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,263.37 +1,456.90 (+2.52%) CMC Crypto 200
1,279.12 +8.38 (+0.66%)
Lexicon Pharmaceuticals, Inc. (LXRX)
After hours:
| Previous close | 1.6500 |
| Open | 1.7500 |
| Bid | 1.6900 x 1400 |
| Ask | 1.7200 x 1800 |
| Day's range | 1.6500 - 1.7500 |
| 52-week range | 0.9200 - 3.7900 |
| Volume | |
| Avg. volume | 4,571,139 |
| Market cap | 418.603M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
GuruFocus.comLexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
Exploring the Financial and Operational Milestones of Lexicon Pharmaceuticals in the First Quarter of 2024
GlobeNewswireLexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Commercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to begin mid-year 2024 Enrollment in Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain on track for expected Q2 2025 topline data Conference Call and Webcast at 5:00 pm Eastern Time THE WOO
- GlobeNewswire
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company. The board of directors has initiated a search for a new chief executive officer which will consider both internal and external candidates. “During Mr. Coats’ tenure, Lexicon advanc
